Detail akcie OS Therap Rg online

Business Summary: OS Therapies Incorporated is a clinical-stage oncology company focused on the identification, development, and commercialization of new class immunotherapy candidates for solid tumors, beginning with osteosarcoma and other solid tumors. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, OS Therapies Inc revenues was not reported. Net loss applicable to common stockholders increased from $5.9M to $15.3M. Higher net loss reflects General & Administrative increase from $1.9M to $9.2M (expense), Research & Development Expenses - Balanc increase from $1.6M to $7.6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.28 to -$0.58.